Cholinesterase Inhibitors
"Cholinesterase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.
Descriptor ID |
D002800
|
MeSH Number(s) |
D27.505.519.389.275 D27.505.519.625.120.300 D27.505.696.577.120.300
|
Concept/Terms |
Cholinesterase Inhibitors- Cholinesterase Inhibitors
- Inhibitors, Cholinesterase
- Anticholinesterase Drugs
- Drugs, Anticholinesterase
- Anticholinesterases
- Anticholinesterase Agents
- Agents, Anticholinesterase
- Anti-Cholinesterases
- Anti Cholinesterases
|
Below are MeSH descriptors whose meaning is more general than "Cholinesterase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cholinesterase Inhibitors".
This graph shows the total number of publications written about "Cholinesterase Inhibitors" by people in this website by year, and whether "Cholinesterase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 1 | 1 | 2 |
2006 | 0 | 2 | 2 |
2007 | 0 | 1 | 1 |
2008 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2012 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2019 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholinesterase Inhibitors" by people in Profiles.
-
Racial/ethnic disparities in initiation and persistent use of anti-dementia medications. Alzheimers Dement. 2022 12; 18(12):2582-2592.
-
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. Alzheimers Res Ther. 2020 10 29; 12(1):137.
-
Diagnosis and Management of Dementia: Review. JAMA. 2019 10 22; 322(16):1589-1599.
-
Drug Shortages in Perioperative Medicine: Past, Present, or Future? Anesth Analg. 2015 Aug; 121(2):259-61.
-
Treatment of delirium following cardiac surgery. J Card Surg. 2012 Sep; 27(5):589-93.
-
Hallucinations in Parkinson disease. Nat Rev Neurol. 2009 Jun; 5(6):331-42.
-
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009 May; 8(5):475-90.
-
Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study. Clin Ther. 2008 Jan; 30(1):182-9.
-
Vascular dementia: emerging trends. Semin Neurol. 2007 Feb; 27(1):66-77.
-
Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. Mov Disord. 2006 Oct; 21(10):1741-4.